CN Patent

CN109310697A — 利格列汀和二甲双胍的组合

Assigned to Boehringer Ingelheim International GmbH · Expires 2019-02-05 · 7y expired

What this patent protects

本发明涉及用于治疗慢性肾病CKD患者的利格列汀与二甲双胍的组合。

USPTO Abstract

本发明涉及用于治疗慢性肾病CKD患者的利格列汀与二甲双胍的组合。

Drugs covered by this patent

Patent Metadata

Patent number
CN109310697A
Jurisdiction
CN
Classification
—
Expires
2019-02-05
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.